Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts AARD Hot Sheet
Join SI Premium – FREE
Aardvark Therapeutics (NASDAQ: AARD) reported Q2 EPS of ($0.66), $0.21 better than the analyst estimate of ($0.87).
For earnings history and earnings-related data on Aardvark Therapeutics (AARD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
- Regeneron Pharma (REGN) PT Raised to $980 at Cantor Fitzgerald
- CRH plc (CRH) PT Lowered to $114 at DA Davidson
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
